𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Revisiting the treatment recommendations for chronic hepatitis B

✍ Scribed by Henry L. Y. Chan

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
43 KB
Volume
49
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Chronic hepatitis B: Update of recommend
Chronic hepatitis B: Update of recommendations
✍ Anna S.F. Lok; Brian J. McMahon πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 92 KB

A n estimated 350 million persons worldwide and 1.25 million in the United States are infected with hepatitis B virus (HBV). Hepatitis B carriers are at risk for development of cirrhosis and hepatocellular carcinoma (HCC). The natural history of chronic HBV infection is variable. Persons with chroni

Treatment of chronic hepatitis B
Treatment of chronic hepatitis B
✍ Gary L. Davis πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 365 KB

Treatment of Chronic Hepatitis B Chronic HBV infection is common and affects more than 200 million individuals worldwide. It is estimated that more than 1 million persons in the United States alone are Chronically infected with this virus. Fur-

Suramin treatment for chronic active hep
Suramin treatment for chronic active hepatitis Bβ€”toxic and ineffective
✍ R. H. T. Loke; M. G. Anderson; J. C. Coleman; Dr. I. M. Murray-Lyon; K. N. Tsiqu πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 198 KB

Suramin has recently been shown to inhibit the activity of the duck hepatitis B virus DNA polymerase (DHBV DNAp) in vitro. However, we found no demonstrable in vivo suppression of human hepatitis B virus DNA polymerase (HBV DNAp) activity in three male patients with severe chronic active hepatitis.